CSBR - Champions Oncology, Inc.
| Previous Close | 6.25 |
| Open | 6.26 |
| Bid | 6.13 x 800 |
| Ask | 7.15 x 900 |
| Day's Range | 6.07 - 6.32 |
| 52 Week Range | 5.07 - 15.45 |
| Volume | 4,982 |
| Avg. Volume | 34,075 |
| Market Cap | 73.435M |
| Beta (3Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | Dec 16, 2019 - Dec 20, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.75 |
- Simply Wall St.
We Think Champions Oncology (NASDAQ:CSBR) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Zacks
When Does Market Timing Actually Work? - October 03, 2019
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
- Simply Wall St.
What Does Champions Oncology, Inc.'s (NASDAQ:CSBR) Share Price Indicate?
Champions Oncology, Inc. (NASDAQ:CSBR), which is in the life sciences business, and is based in United States, saw...
- ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $6.7 Million
HACKENSACK, NJ / ACCESSWIRE / September 16, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...
- ACCESSWIRE
Champions Oncology, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 16, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on September 16, 2019 ...
- Zacks
The Truth About Market Timing - September 13, 2019
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
- ACCESSWIRE
Champions Oncology to Announce First Quarter Financial Results on Monday, September 16, 2019
HACKENSACK, NJ / ACCESSWIRE / September 9, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2019, on Monday, September 16, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). A replay of the call will be available by dialing 877-481-4010 and entering Passcode:53656, or by accessing the Investor tab of the company's website within 72 hours.
- Simply Wall St.
How Much is Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Getting Paid?
Ronnie Morris has been the CEO of Champions Oncology, Inc. (NASDAQ:CSBR) since 2017. This report will, first, examine...
- Zacks
Yes, You Can Time the Market. Find out How - August 26, 2019
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
- Zacks
Simple Market Timing Strategies That Work - August 05, 2019
In the long-run, does consistent market timing really matter to be a successful investor?
- GuruFocus.com
Champions Oncology Inc (CSBR) Files 10-K for the Fiscal Year Ended on April 30, 2019
Champions Oncology Inc (CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019. Continue reading...
- Simply Wall St.
Champions Oncology, Inc. (NASDAQ:CSBR) Delivered A Weaker ROE Than Its Industry
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- ACCESSWIRE
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019
Record Annual Revenue of $27 Million HACKENSACK, NJ / ACCESSWIRE / July 15, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize ...
- ACCESSWIRE
Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 15, 2019
HACKENSACK, NJ / ACCESSWIRE / July 12, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter ended April 30, 2019, on Monday, July 15, 2019, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 and entering Passcode: 50412, or by accessing the Investor tab of the company's website within 72 hours.
- Simply Wall St.
Calculating The Intrinsic Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Today we will run through one way of estimating the intrinsic value of Champions Oncology, Inc. (NASDAQ:CSBR) by...
- Simply Wall St.
How Many Champions Oncology, Inc. (NASDAQ:CSBR) Shares Have Insiders Sold, In The Last Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- ACCESSWIRE
Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations
HACKENSACK, NJ / ACCESSWIRE / May 30, 2019 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced they have partnered with TransCure bioServices to expand the pharmacology operations of Champions' translational oncology tools throughout Europe. Champions' European customers can continue their unique and consultative interactions with the Champions business development and project leadership teams, along with the option of performing the pharmacology work locally. An operations solution in Europe reduces the intercontinental logistics involved with performing the work in the US.
- Simply Wall St.
What Kind Of Shareholder Owns Most Champions Oncology, Inc. (NASDAQ:CSBR) Stock?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Champions Oncology, Inc. (NASDAQ:CSBR) should be aware of the most powerful shareho...
- Zacks
Moving Average Crossover Alert: Champions Oncology
Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- Zacks
New Strong Sell Stocks for April 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks
New Strong Sell Stocks for April 1st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks
New Strong Sell Stocks for March 27th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:
- ACCESSWIRE
Champions Oncology Reports Quarterly Revenue of $6.4 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / March 18, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of ...
- ACCESSWIRE
Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019
HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...
- Zacks
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
